ReviewCancer cell2013
Histone H3.3 mutations: a variant path to cancer.
Review in Cancer cell, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis.Scientific reports · 2021Pooled it
- H3K27 trimethylation loss in malignant peripheral nerve sheath tumor: a systematic review and meta-analysis with diagnostic implications.Journal of neuro-oncology · 2019Pooled it
- H3.3G34W immunohistochemistry negative giant cell tumour of bone. Extended analysis of 35 such cases from a single institution in India.Virchows Archiv : an international journal of pathology · 2026Article
- Evidence for coordinate CTCF and histone H3.3 activities in K27M diffuse midline gliomas.Acta neuropathologica communications · 2026Article
- Illuminating radiogenomic signatures in pediatric-type diffuse gliomas: insights into molecular, clinical, and imaging correlations. Part I: high-grade group.La Radiologia medica · 2025Review
- H3F3A K27M mutations drive a repressive transcriptome by modulating chromatin accessibility independent of H3K27me3 in Diffuse Midline Glioma.Epigenetics & chromatin · 2025Article
- The Pivotal Role of LACTB in the Process of Cancer Development.International journal of molecular sciences · 2025Review
- Exercise and tumor proteome: insights from a neuroblastoma model.Physiological genomics · 2024Article
- From bedside to bench: New insights in epilepsy-associated tumors based on recent classification updates and animal models on brain tumor networks.Molecular oncology · 2024Review
- Roles of Histone H2B, H3 and H4 Variants in Cancer Development and Prognosis.International journal of molecular sciences · 2024Review
- Histone 3.3-related chromatinopathy: missense variants throughout H3-3A and H3-3B cause a range of functional consequences across species.Human genetics · 2024Review
- Knockout tales: the versatile roles of histone H3.3 in development and disease.Epigenetics & chromatin · 2023Review
- Review
- Darinaparsin (ZIO-101) enhances the sensitivity of small-cell lung cancer to PARP inhibitors.Acta pharmacologica Sinica · 2023Article
- A knockout-first model of H3f3a gene targeting leads to developmental lethality.Genesis (New York, N.Y. : 2000) · 2023Article
- Loss of Nexmif results in the expression of phenotypic variability and loss of genomic integrity.Scientific reports · 2022Article
- Dissecting cell fate dynamics in pediatric glioblastoma through the lens of complex systems and cellular cybernetics.Biological cybernetics · 2022Review
- Incorporation of a histone mutant with H3K56 site substitution perturbs the replication machinery in mouse embryonic stem cells.Journal of molecular cell biology · 2022Article
- Histone H3.3 K27M chromatin functions implicate a network of neurodevelopmental factors including ASCL1 and NEUROD1 in DIPG.Epigenetics & chromatin · 2022Article
- Unravelling the Proteomics of HLA-B*57:01Journal of personalized medicine · 2022Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
A host of cancer types exhibit aberrant histone modifications. Recently, distinct and recurrent mutations in a specific histone variant, histone H3.3, have been implicated in a high proportion of malignant pediatric brain cancers. The presence of mutant H3.3 histone disrupts epigenetic posttranslational modifications near genes involved in cancer processes and in brain function. Here, we review possible mechanisms by which mutant H3.3 histones may act to promote tumorigenesis. Furthermore, we discuss how perturbations in normal H3.3 chromatin-related and epigenetic functions may more broadly contribute to the formation of human cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.